Fate Therapeutics (FATE) Current Assets (2012 - 2026)

Fate Therapeutics has reported Current Assets for 15 years, with the latest figure at $179.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 27.67% year-over-year to $179.5 million; the trailing twelve-month figure through Mar 2026 stood at $179.5 million (down 27.67% YoY), and the FY2025 full-year result was $208.7 million, down 28.5% from the prior year.
• Current Assets for Q1 2026 stood at $179.5 million, down from $208.7 million in the prior quarter.
• The five-year high for Current Assets was $599.2 million in Q2 2022, with the low at $179.5 million in Q1 2026.
• Historically, Current Assets has averaged $362.7 million across 5 years, with a median of $331.5 million in 2023.
• Annual changes were most pronounced in 2024 — Current Assets decreased 9.94% — and 2025, when it sank 37.06%.
• Fate Therapeutics' Current Assets stood at $502.1 million in 2022, then tumbled by 33.97% to $331.5 million in 2023, then slipped by 11.95% to $291.9 million in 2024, then retreated by 28.5% to $208.7 million in 2025, then retreated by 13.98% to $179.5 million in 2026.
• The last three Current Assets figures came in at $179.5 million (Q1 2026), $208.7 million (Q4 2025), and $221.3 million (Q3 2025), per Business Quant data.